Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Rapaflo, Urief, Silodyx, Setegis
Silodosin is a selective α1A-adrenergic receptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It works by relaxing the smooth muscle in the prostate and bladder neck, improving urine flow and reducing BPH symptoms. Silodosin belongs to the class of drugs known as alpha-blockers.
For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Outcome:
Increased risk of hypotension
Mechanism:
Both drugs can lower blood pressure.
Outcome:
Additive hypotensive effects
Mechanism:
Combined blood pressure lowering effects.
Outcome:
Reduced silodosin absorption
Mechanism:
Chelation or altered gastric pH.
Most likely new formulation: Extended-release silodosin (2026, 70% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that silodosin will maintain its current regulatory status for the next 5 years.
Alpha-1A-adrenergic receptor antagonist
Indole